Cellectis SA Sustainability Reports
Cellectis S.A. is a clinical-stage biopharmaceutical company focused on developing next-generation gene-edited CAR T-cell immunotherapies to treat cancer.
Sector: Professional & technical services
Country: France
Exchange: Euronext Paris
LEI: 5493000KKX5VQ37Q2W83
FIGI: BBG001S9FQ03
9 reports from 2012 to 2025
